Hinna Askell Hvid, Hupfeld Stefan, Kuntsche Judith, Brandl Martin
University of Southern Denmark, Department of Physics, Chemistry and Pharmacy, Campusvej 55, DK-5230 Odense, Denmark.
Aker Biomarine Antarctic AS, Oksenøyveien 10, P.O. Box 496, NO-1327, Lysaker, Norway.
J Pharm Biomed Anal. 2016 May 30;124:157-163. doi: 10.1016/j.jpba.2016.02.037. Epub 2016 Mar 2.
Due to their solubilizing capabilities, liposomes (phospholipid vesicles) are suited for designing formulations for intravenous administration of drug compounds which are poorly water-soluble. Despite the good in-vitro stability of such formulations with minimal drug leakage, upon i.v. injection there is a risk of premature drug loss due to drug transfer to plasma proteins and cell membranes. Here we report on the refinement of a recently introduced simple in vitro predictive tool by Hinna and colleagues in 2014, which brings small drug loaded (donor) liposomes in contact with large acceptor liposomes, the latter serving as a model mimicking biological sinks in the body. The donor- and acceptor-liposomes were subsequently separated using asymmetrical flow field-flow fractionation (AF4), during which the sample is exposed to a large volume of eluent which corresponds to a dilution factor of approximately 600. The model drug content in the donor- and acceptor fraction was quantified by on-line UV/VIS extinction measurements with correction for turbidity and by off-line HPLC measurements of collected fractions. The refined method allowed for (near) baseline separation of donor and acceptor vesicles as well as reliable quantification of the drug content not only of the donor- but now also of the acceptor-liposomes due to their improved size-homogeneity, colloidal stability and reduced turbidity. This improvement over the previously reported approach allowed for simultaneous quantification of both drug transfer and drug release to the aqueous phase. By sampling at specific incubation times, the release and transfer kinetics of the model compound p-THPP (5,10,15,20-tetrakis(4-hydroxyphenyl)21H,23H-porphine) was determined. p-THPP is structurally closely related to the photosensitizer temoporfin, which is in clinical use and under evaluation in liposomal formulations. The transfer of p-THPP to the acceptor vesicles followed 1st order kinetics with a half-life of approximately 300 min. As expected, equilibrium distribution between donor- and acceptor vesicles was proportional to the lipid mass ratio. An initial rapid transfer of p-THPP was found (∼ 5%) and investigated further by determining the extent of transfer between donor and acceptor during separation. The donor- and acceptor phase were found to be separated within few minutes and only minor (≤ 2%) transfer could be detected within the AF4 channel under the conditions applied for fractionation. These results demonstrates the potential of our AF4 based method as an in vitro tool to determine retention properties of lipophilic compounds within liposomal carriers in particular, but also within a variety of nano-particulate carriers provided that they exhibit a sufficient size difference compared to the applied colloidal acceptor phase.
由于具有增溶能力,脂质体(磷脂囊泡)适用于设计难溶性药物化合物的静脉给药制剂。尽管此类制剂在体外具有良好的稳定性,药物泄漏极少,但静脉注射时,由于药物转移至血浆蛋白和细胞膜,仍存在药物过早流失的风险。在此,我们报告了对Hinna及其同事在2014年引入的一种简单体外预测工具的改进,该工具使载有少量药物的(供体)脂质体与大型受体脂质体接触,后者作为模拟体内生物汇的模型。随后使用不对称流场流分馏(AF4)分离供体脂质体和受体脂质体,在此过程中,样品暴露于大量洗脱液中,洗脱液的稀释因子约为600。通过在线紫外/可见消光测量并校正浊度以及对收集馏分进行离线高效液相色谱测量,对供体馏分和受体馏分中的模型药物含量进行定量。改进后的方法实现了供体囊泡和受体囊泡的(近乎)基线分离,并且由于其尺寸均一性提高、胶体稳定性增强和浊度降低,不仅能够可靠地定量供体脂质体中的药物含量,现在还能定量受体脂质体中的药物含量。与先前报道的方法相比,这一改进使得能够同时定量药物转移和药物向水相的释放。通过在特定孵育时间取样,测定了模型化合物p - THPP(5,10,15,20 - 四(4 - 羟苯基)21H,23H - 卟啉)的释放和转移动力学。p - THPP在结构上与正在临床使用且正在脂质体制剂中进行评估的光敏剂替莫泊芬密切相关。p - THPP向受体囊泡的转移遵循一级动力学,半衰期约为300分钟。正如预期的那样,供体囊泡和受体囊泡之间的平衡分布与脂质质量比成正比。发现p - THPP有初始快速转移(约5%),并通过测定分离过程中供体与受体之间的转移程度进行了进一步研究。发现在几分钟内供体相和受体相就被分离,在用于分馏的条件下,在AF4通道内仅能检测到少量(≤2%)的转移。这些结果证明了我们基于AF4的方法作为一种体外工具的潜力,该工具不仅可用于确定亲脂性化合物在脂质体载体中的保留特性,特别是在各种纳米颗粒载体中,如果它们与所应用的胶体受体相比表现出足够的尺寸差异,也可用于确定亲脂性化合物在其中的保留特性。